Lipigon Q1 2023: Preparing for Phase II - Redeye

Redeye comments on Lipigon’s first-quarter report. After the end of Q1, all patients in the phase I study of Lipisense have been treated without any serious adverse events. The data is being analysed at the same time as a phase IIa study is being planned towards the end of the year.

Länk till analysen i sin helhet: https://www.redeye.se/research/912230/lipigon-q1-2023-preparing-for-phase-ii?utm_source=finwire&utm_medium=RSS